Skip to content

The effectiveness of mirtazapine in reducing dependence and the temptation to consume amphetamine and methamphetamine in patients

Investigating the effectiveness of mirtazapine in reducing dependence and the temptation to consume amphetamine and methamphetamine patients referred to addiction treatment clinics

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT20230606058397N1
Enrollment
84
Registered
2023-09-18
Start date
2023-09-23
Completion date
Unknown
Last updated
2023-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Methamphetamine.

Interventions

Intervention group: 84 patients referred to Golestan hospital clinic, who were diagnosed by a psychiatric specialist based on DSM V diagnosis criteria, entered the study and were randomly assigned to

Sponsors

Ahvaz University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: At least one positive urine test for methamphetamine during the hospitalization period Absence of current acute illness Absence of serious chronic diseases Able and willing to provide informed consent and adhere to the visit schedule

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Decreasing addiction in patients using amphetamine and methamphetamine. Timepoint: Before starting the treatment, at the beginning of the treatment and once every two weeks (the length of the treatment is 12 weeks), the results will be measured. Method of measurement: With physical examinations and measurement of vital signs, evaluation with the dependency index questionnaire.

Secondary

MeasureTime frame
Reducing depression in patients using amphetamine and methamphetamine. Timepoint: Before starting the treatment, at the beginning of the treatment and once every two weeks (the length of the treatment is 12 weeks), the results will be measured. Method of measurement: with Beck depression questionnaire, physical examinations and measuring vital signs.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad Hossein Salehi Kasai

Ahvaz University of Medical Sciences

ehsanmoradijoo@yahoo.com+98 61 3356 6523

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026